I t has long been known that behaviour and emotional problems occur at high rates in people with IDs and DDs. 1 It is also well established that these problems can start at an early age and persist throughout the lifespan. 2, 3 Behaviour and emotional problems are costly to society and may ostracize people and their caregivers, clearly a countercurrent to the present zeitgeist of inclusion. These problems can be quite stressful and dangerous for caregivers. For these reasons, psychopathology has long been, and continues to be, one of the central issues of DDs. The 2 comprehensive reviews 4, 5 provide an accurate depiction of the present state of affairs in IDs and ASD.
In the first review, Dr Johnny L Matson and colleagues 4 discuss discrepancies between clinical realities and best evidence practice. My own experience converges with these observations: psychiatric diagnoses are misunderstood and behavioural technologies are underused. Why is it so? An obvious explanation for the diagnostic challenges is that self-report is of limited value in many people with DDs, who, by definition, have impaired insight and communication skills. Until new technologies are developed, caregiver observations will be at the forefront of diagnostic endeavours. Numerous rating instruments have been developed but the gold standard continues to remain elusive. As a result, fundamental issues, such as phenomenology, prevalence, comorbidity, and course of psychopathology, are not well understood. This measurement problem impacts the possibility of replicating findings, which is at the heart of scientific progress. Simply put, we do not know to what extent intellectual deficits or ASD alter the typical clinical presentation of psychiatric syndromes.
In many ways, diagnostic difficulties are inherent to DDs, especially in lower-functioning people. Suboptimal use of behavioural technology is a different story. Functional assessments are not used as much as they should be. Treatment decisions are often not data-driven. We can reflect on these issues in terms of efficacy and effectiveness. Efficacious treatments are those that prove beneficial for patients in well-controlled treatment studies. Effectiveness entails showing that efficacious treatment can be transported from the research setting to the community where there is more variation in subject selection and treatment implementation. No serious scientist would argue against the validity of operant conditioning. It is the short-term cost and practicalities that hamper optimal use of many behavioural methods. One of the biggest challenges to applied behavioural interventionists is undoubtedly the transfer of technology in a world with increased regulations and financial constraints and high staff burnout and turnover.
In the second review, Dr Peter Sturmey 5 provides a synthesis of the treatment literature in DDs. The review shows that there are many publications on the topic. Conversely, it indicates that the available evidence for treatments is quite limited. Of course, a distinction must be made between ineffective or harmful treatments and those that are not currently supported by enough quality research. Most (but not all) applied researchers would agree that rigorous treatment studies entail randomization, comparison to alternative treatments, blind evaluations, standardized outcome measures, standardized doses, and a large enough sample size for meaningful analyses and generalization of results. 6 proportion of the population has a DD, which makes study recruitment a serious obstacle. Imagine the researcher who wants to study the safety and efficacy of an alpha agonist on hyperactivity and aggression in adults with ASD. Prospective participants are adults with ASD who meet study criteria on measures of ADHD and aggression. They should be in fairly good physical health, free of other psychotropics, and, of course, willing to be randomized in a study. One quickly realizes that an already-low population base rate shrinks considerably, making timely recruitment a real challenge. No wonder there are no polypharmacy studies, despite the clinical reality that this is more a rule than an exception! In dollar terms, multisite cooperative agreements, such as the Research Units on Pediatric Psychopharmacology sponsored by the National Institute of Mental Health, are a rather costly solution to recruiting low-incidence disorders.
Despite the logistical difficulties inherent to the population, a considerable amount of literature has been published on the treatment of behaviour and emotional problems in adults with IDs. Most reasonable people would agree that behavioural and pharmacological approaches can have positive outcomes in this population. The real question is not whether behavioural or pharmacological treatments work, but rather which specific treatment works for whom and under which circumstances? At the moment, there are virtually no large-scale, controlled trials of psychosocial or pharmacological treatments in adults with DD that allow us to examine moderation and mediation. 8 To complicate matters, there is great genetic and phenotypic heterogeneity in the population with DDs. This can lead to highly variable study samples and reduce the potential effect size for given treatments.
Although I agree with the conclusion that there is good evidence in support of behavioural interventions, my optimism is tempered by methodological shortcomings of many of the studies. I use a recent review 9 on DR to reduce behaviour problems in adults with IDs to illustrate the point. DR is a widely used intervention for various behaviour problems. It is favoured by many because it is a nonaversive, reinforcement-based technique. During a 30-year span, 31 studies on DR were located (all of which were single-subject designs). There was a total of only 48 subjects, across all studies combined, most of whom had severe intellectual delays. More than one-half of the studies had the DR as part of a larger treatment package, and many studies used a less than ideal AB research design. Twentyfive of the 31 studies found DR to be effective. I do not question the idea that DR can reduce behaviour problems. However, the situations under which DR works and does not work are unclear (that is, which people respond best? which behaviours are amenable to change? and what is the necessary dose for effective treatment?). This is certainly not an argument against single-subject design research. It is a call for more research on the moderators and mediators of behavioural treatment efficacy.
Two additional observations are worthy of discussion. First, it is notable that most research focuses on single treatments used in isolation. This is quite different from reality, where most patients with DD are involved in several treatments simultaneously. I am aware of only one large-scale study 10 that examined a combination of treatments in DDs (risperidone and parent training in behaviour interventions in children with ASD and irritable behaviour). There is an obvious need for more research on combined treatments. Second, it is important to be mindful that we treat behaviour and emotional problems with the idea that it will result in significant positive life adjustments for the individual, such as less restrictive vocational or living arrangements. Very few studies go beyond symptom reduction and actually measure constructs such as impairment, adaptive behaviour, or quality of life.
Assessing and treating behaviour and emotional problems in people with DD is a complex enterprise. Research in the area is wrought with obstacles. Some of the obstacles, such as cognitive problems and low base rates, are inherent to the population. Others, such as transfer of technology, can be overcome with training and research. Different lenses lead to different conclusions: the glass is half empty in light of the current limited evidence for effective treatments, but it is half full when one considers the increased quantity and quality of research in the last 20 years.
